Navigation Links
New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
Date:5/9/2011

CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population.  The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in 73 percent of patients aged 6-17 years at week 8, the primary endpoint of the trial.  REMICADE received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active UC in September 2005 and in October 2006, REMICADE received FDA approval for maintaining clinical remission and mucosal healing indications in adults living with UC.

UC is a chronic inflammatory bowel disease (IBD) of the colon.  It is estimated that 1.4 million Americans have IBD with the number evenly split between UC and Crohn's disease.  An estimated 150,000 children under age 17 are living with debilitating symptoms of IBD.(1)  

"The results of this study are consistent with findings from the Active Ulcerative Colitis (ACT) trials, which evaluated REMICADE in the treatment of adults with ulcerative colitis," said Jeffrey Hyams, Head of the Division of Digestive Diseases and Nutrition at Connecticut Children's Medical Center and Professor of Pediatrics at University of Connecticut School of Medicine, and lead study investigator.  "UC can be a devastating disease, particularly for children and adolescents.  It is encouraging to see such promising results in a patient population that is in need of additional treatment options."

In December 2010, Centocor Ortho Biotech Inc. submitted a supplemental Biologics License Application (sBLA) to the FDA requesting the approval of REMICADE (infliximab) for the treatment of modera
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Cell ... their offering. This report describes and ... already started to play an important role in ... is replacing the old fashioned bone marrow transplants. ...
(Date:5/28/2015)... 2015 Natera, Inc., a leader in ... in Ultrasound in Obstetrics & Gynecology ... prenatal test (NIPT) can identify a complete molar ... A study based upon data collected in the ... about 1 in 1,000 pregnancies, although other studies ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
(Date:5/28/2015)... 2015 The Fertility Centers of New ... Danielle Vitiello has taken on a new and expanded ... will provide guidance, leadership, oversight and quality assurance for ... Vitiello among our team of experienced reproductive endocrinologists,” said ... A. Hill, M.D. “Her expertise and compassionate, individualized care ...
Breaking Biology Technology:Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... , , BEIJING , Feb. 8 /PRNewswire-Asia-FirstCall/ -- ... today announced that it will participate at the,following investor conferences in March 2010 : , , ... Location, Rodman & Renshaw ... China Investment ...
... , DENVER and NEW ORLEANS , ... CONX), a worldwide developer and marketer of diagnostic test kits, and ... collaborative effort to combat viral hemorrhagic fever (VHF), an effort that ... Corgenix over the life of the contract. , The National ...
... , NEW YORK , Feb. 8 ... in investor relations and corporate communications for domestic and international ... Matthew Haines have joined as Managing Directors. , ... that will serve our clients well,” said Lynn Morgen ...
Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7MBS Value Partners Hires Two New Senior Staff Members 2
(Date:5/26/2015)... DUBLIN , May 26, 2015 ... has announced the addition of the "Saudi ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Saudi Arabia is projected to grow ... This high growth is attributed to the surging ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2
... Researchers at the University of North Carolina at Chapel ... paste together different viruses in an effort to create the ... trial, the investigators found no side effects from using a ... protein in patients with muscular dystrophy. "This trial demonstrates ...
... dish containing crude petroleum and it will release a strong ... fuel. Sprinkle mushroom spores over the Petri dish and let ... the petroleum and its smell will disappear. "The mushrooms consumed ... and researcher at the University of Montreal,s Institut de recherche ...
... ADFLOW Health Networks, the industry leader in patented ... Engagement and Marketing, announced today it will be ... Aid locations. (Logo: http://photos.prnewswire.com/prnh/20111019/PH89532LOGO ... demonstrates Rite Aid,s commitment to transforming customer wellness ...
Cached Biology News:Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2Petroleum-eating mushrooms 2Petroleum-eating mushrooms 3Petroleum-eating mushrooms 4ADFLOW Health Networks to Provide Blood Pressure Screening Centers at Rite Aid Pharmacies Nationwide 2
Request Info...
... the secretion of cytoplasmic granules, is ... response of leukocytes (e.g. basophils, neutrophils, ... to histamine, these secretory granules contain ... chemokines, and many proteases (Hallgren, 2001). ...
... The S&S Custom Processing Service enables scientists who ... and data analysis software to have their biological ... 16 analytes. Its as easy as 1-2-3 ... quantified in your samples from the S&S antibody ...
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Biology Products: